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Abstract: There is an urgent need to treat individuals with high blood pressure (BP) with 
effective dietary strategies. Previous studies suggest a small, but significant decrease in BP 
after lactotripeptides (LTP) ingestion, although the data are inconsistent. The study aim was 
to perform a comprehensive meta-analysis of data from all relevant randomised controlled 
trials (RCT). Medline, Cochrane library, EMBASE and Web of Science were searched until 
May 2014. Eligibility criteria were RCT that examined the effects of LTP on BP in adults, 
with systolic BP (SBP) and diastolic BP (DBP) as outcome measures. Thirty RCT met the 
inclusion criteria, which resulted in 33 sets of data. The pooled treatment effect for SBP was 
−2.95 mmHg (95% CI: −4.17, −1.73; p < 0.001), and for DBP was −1.51 mmHg (95% CI: 
−2.21, −0.80; p < 0.001). Sub-group analyses revealed that reduction of BP in Japanese 
studies was significantly greater, compared with European studies (p = 0.002 for SBP and  
p < 0.001 for DBP). The 24-h ambulatory BP (AMBP) response to LTP supplementation 
was statistically non-significant (p = 0.101 for SBP and p = 0.166 for DBP). Both  
publication bias and “small-study effect” were identified, which shifted the treatment  
effect towards less significant SBP and non-significant DBP reduction after LTP 
consumption. LTP may be effective in BP reduction, especially in Japanese individuals; 
however sub-group, meta-regression analyses and statistically significant publication biases 
suggest inconsistencies. 
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1. Introduction 
Cardiovascular diseases (CVD) remain the major cause of death worldwide, with a further expected 
increase by 2030 [1]. A large body of evidence suggests that high BP is one of the most important 
controllable risk factors of CVD, responsible for 13% of deaths in the world annually, and is a leading 
global risk for mortality [2]. High BP can be asymptomatic, thus many hypertensive individuals are 
unaware of its existence. However, it may cause serious damage to organs such as the heart, kidneys or 
eyes. Therefore, even a small reduction in BP of 2–5 mmHg is clinically significant and can have a major 
impact on public health [3]. Environmental factors, including diet and lifestyle, have a direct effect on 
hypertension, with health authorities recommending the adoption of a healthy diet and lifestyle for 
individuals with raised BP, in addition to healthy people, as a preventive measure against the development 
of hypertension [4]. 
In the last two decades both scientific and commercial attention has focused on the beneficial effects 
of milk proteins and peptides on human health as a potential ingredient for functional foods aimed at 
controlling elevated BP. The release of antihypertensive milk peptides from the intact protein can be 
achieved by: fermentation with proteolytic starter cultures; hydrolysis by various enzymes produced by 
microorganisms or enzymatic hydrolysis in the gastrointestinal digestion [5]. lactotripeptides (LTP)—
valine-proline-proline (VPP) and isoleucine-proline-proline (IPP), which can be released from β-casein 
and κ-casein—are the two most investigated casein-derived peptides in both animal and human studies. 
To date, there are four meta-analyses that specifically addressed the effect of LTP on BP; however 
Xu et al. [6] included only nine randomised controlled trials (RCT), while Cicero et al. [7] performed a 
meta-analysis on 18 RCT. The most recent meta-analyses were conducted by Turpeinen et al. which 
included 19 RCT [8], and by Qin et al. which analysed 24 studies resulting in 28 trials [9]. Despite the 
growing number of meta-analyses, to date, most included a restricted number of available published studies, 
limited sub-group, meta-regression and publication bias analyses. Therefore the aim of this study was to 
conduct a meta-analysis on all available published RCT, which complied with strict predefined criteria, 
to provide a more accurate estimate of the true treatment effect of LTP ingestion. Furthermore we aimed 
to carefully scrutinise the relationship between study-level covariates and effect size as well as sub-
group analyses and publication bias. Additionally our goal was to review and critically evaluate the 
existing meta-analyses, which exclusively focused on the effects of LTP on BP. Thus this more precise, 
comprehensive and independent analysis will help both researchers, policy makers and the industry to 
determine whether LTP consumption is an effective strategy for hypertension reduction and prevention. 
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2. Experimental Section 
2.1. Protocol 
Both the inclusion criteria and methods of analysis were specified prior to commencement and the 
PRISMA [10] guidelines were employed for this review. 
2.2. Eligibility Criteria for Meta-Analysis 
The eligibility criteria for studies to be included in the meta-analysis were: RCT that examined the 
effects of LTP on BP in men and women aged 18 or above, whose outcome measure was a change in 
SBP or DBP. The primary outcome measure considered in the meta-analysis was data from office BP 
measurement, however when these were not reported, data from AMBP or home measurements were 
used. The secondary outcome measure was AMBP. The intervention products had to contain LTP, were 
orally administered (at any dose or frequency) and the duration of intervention had to be a minimum of 
4 weeks. All studies had to include a control arm. 
2.3. Information Sources and Search Strategy 
The literature search was performed using the following electronic databases: MEDLINE, PUBMED, 
the Cochrane Library, EMBASE and Web of Science using the following terms: intervention, 
randomised controlled trials, clinical trials, high blood pressure, hypertension, anti-hypert*,  
milk protein, milk peptides, casein, hydrolysate, lactotripeptides*, tripeptide*, VPP, IPP, Ile-Pro-Pro, 
Val-Pro-Pro, fermented, sour, humans (see Supplementary Information). Furthermore, hand-searching 
was performed on the reference lists of both eligible studies and review articles. In addition, Google and 
Google Scholar were searched to confirm that the search was complete. Authors were contacted in cases 
of incomplete information reported in articles or for reprints of articles when they were not retrievable 
online. The search period covered studies published in any language until 1 May 2014. 
2.4. Study Selection, Data Collection Process and Data Items 
Titles and abstracts were screened to determine whether they met the inclusion criteria; articles which 
were not relevant were immediately excluded. Manuscripts were reviewed and the following information 
was extracted: 1) study design (randomised, parallel, crossover); 2) characteristics of the subjects (BP 
status, age, gender, BMI, treatment with antihypertensive medication); 3) intervention (type of 
intervention product, duration, frequency, dose, type of placebo); 4) method of BP measurement (office, 
AMBP, home); 5) change in SBP and DBP from baseline, and change in BP compared to placebo group. 
All literature was selected and assessed by AAF, with two further researchers (JAL and DIG) 
independently reviewing 20% of all papers to validate the procedure. It is common practice that if 
discrepancies in decisions between the reviewers occur, a fourth investigator is consulted. However in 
this analysis this was not required as no discrepancies were identified. Data collection and statistical 
analysis were conducted by AAF under the supervision of a statistician. 
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2.5. Risk of Bias in Individual Studies 
Manuscripts were assessed for potential risk of bias according to PRISMA guidelines [10] and the 
Cochrane Handbook [11]. Studies that met the inclusion criteria were categorised as high, medium or 
low quality based on appropriate generation of random allocation sequence, concealment of allocation, 
blinding, incomplete outcome data, selective reporting, and other bias. A trial was considered to be of 
low quality when more than three unclear risks or two high risks of bias were identified; of medium 
quality when less or equal to three unclear risks or one high risk were identified; and of high quality 
when less or equal to one unclear risk was stated. Low risk was considered when the judgement for a 
criteria was “yes” (i.e., was the allocation sequence adequately generated?); high risk, when the 
judgement was “no”; and unclear risk, when it was uncertain [11]. 
2.6. Summary Measures and Synthesis of Results 
The outcome measure was the difference in means using random effect model. For parallel trials, the 
treatment effect was calculated by subtracting the change in SBP or DBP from baseline in treatment 
group from the change in SBP or DBP from baseline in placebo group. For cross-over trials, the given 
calculated differences in means were used. When more than one dose was used the data from the highest 
dose group was extracted for the meta-analysis. In order to impute the standard deviation of the treatment 
effect, a correlation between pre- and post-BP of 0.5 was used [12]. Q statistics was used to test for 
heterogeneity and p < 0.05 was considered statistically significant. Data analysis and synthesis were 
performed using Comprehensive Meta-analysis version 2.0 [13]. 
Pre-specified sub-group analyses (with random effects model) on baseline average BP, duration of 
intervention, type of LTP production, dose of LTP and countries of studies were conducted. For the 
analysis of study countries, trials were grouped as Japanese and European studies, since a previous  
meta-analysis suggested that Japanese and European studies showed remarkable BP lowering after LTP 
supplementation [7]. Differences between sub-groups were assessed manually by significance tests 
described by Borenstein et al. [14]. We performed random effects meta-regression using weights 
proportional to the inverse variance on dose of LTP, age and BMI of participants. The extent to which 
the heterogeneity was explained by the covariates was also calculated. Furthermore, publication bias 
was assessed both visually and formally by evaluating a funnel plot of mean difference for both SBP 
and DBP and by statistical tests (Begg and Mazumdar rank correlation test (which computes the rank 
order correlation (Kendall’s tau b) between the treatment effect and the standard error (which is driven 
primarily by sample size)), Egger’s test of the intercept (using precision (the inverse of the standard 
error) to predict the standardized effect) and Duval and Tweedie’s trim and fill (determining where  
the missing studies are likely to fall, adding them to the analysis, and then recalculating the  
combined effect.)). 
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3. Results 
3.1. Study Selection 
The search of mainstream and other databases as well as the list of references yielded a total of  
249 studies (see Supplemental Figure S1.). Reviewing the titles and abstracts resulted in the exclusion 
of 192 studies, which did not meet the inclusion criteria (conference abstracts were excluded due to the 
limited reported information on the trials). Therefore full manuscripts of the remaining 58 articles were 
obtained in order to examine them in more detail. A total of seven [15–21] studies were excluded as they 
appeared to use whey protein or associated peptides as an intervention product. The remaining 53 studies 
used casein or its associated peptides. Of the 52 studies identified, 45 used LTP and five used  
other peptides such as C12 peptide (Phe-Phe-Val-Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys) [22–25], or 
serine-lysine-valine-tyrosine-proline peptide [26], and two used intact casein [20,21], which were 
excluded from the analysis. 
A total of 30 studies met the selection criteria. The reason for study exclusion included studies which 
were not randomised (n = 3) [27–29], trials investigating postprandial responses (n = 1) [30], preliminary 
studies (n = 3) (no control group used) [31–33], inclusion of plant sterols in the intervention product  
(n = 2) [34,35], duplicate publication (n = 1) [36], no measure of BP (n = 1) [37], insufficient data  
(n = 2) [38,39], intervention duration was less than four weeks [40,41], and in Japanese and unable to 
be translated (n = 1) [42]. When the nutritional intervention included LTP and LTP with other 
intervention (e.g., exercise) [43,44] or substances [45,46] (e.g., other LTP or K+), only data from LTP 
supplementation arm and control were used. When different doses of LTP were tested, the result from 
the highest dose was included [47–50,51]. 
3.2. Study Characteristics 
The 30 studies involving 33 clinical trials were published between 1996 and 2014 (see Table 1.). The 
majority of studies used a parallel design and double blinding, however five studies used cross-over 
design [45,46,52–54], three trials were single blinded [43,44,48] and one failed to specify blinding [54]. 
All cross-over studies involved wash-out periods ranging from one to four weeks, apart from one  
study [45], which did not have a wash-out period, justifying it with the short half-life of LTP, and another 
study did not mention a wash-out period [54]. The duration of interventions varied between 4–21 weeks 
and the average duration was 7.8 weeks. 
The 30 papers included a total of 2200 (1184 males, 1016 females) participants (who were randomised 
to treatments), with a mean of 64.7 subjects per trial. The average dose of LTP was 10.5 mg/day  
(5.2 mg/day of IPP and 5.3 mg/day of VPP). Of the studies included in the meta-analysis, 14 (47%) were 
performed in Japan [43,44,48,55–57,58–65], six (20%) in Finland [50–52,66–68], four (13%) in the 
Netherlands [45,49,69,70], three (10%) in Italy [53,54,71], one (3%) in the USA [72], one (3%) in 
Denmark [47] and one (3%) in Scotland [46]. The baseline SBP of participants ranged between  
110–160 mmHg and baseline DBP between 65–95 mmHg. Only 9 studies reported their results by 24-h 
AMBP, which resulted in 10 sets of data [46,47,50,51,53,54,67,71]. Germino et al. failed to provide 
DBP results [72]. The study of Engberink et al. was excluded from this analysis, as they failed to report 
AMBP results in an appropriate manner to include into our meta-analysis. Two studies included participants 
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who took anti-hypertensive medication, however the dose and type of medication did not change during 
intervention [55,66]. 
The intervention products were produced by enzymatic hydrolysis and by fermentation in 15 and  
13 trials, respectively, one [69] used three types of LTP products by three different types of production 
method (fermentation, enzymatic hydrolysis and synthetic); and another three [43,44,72] did not specify 
the production process of the product. The food matrices which carried LTP were varied: 10 trials 
involved tablets or capsules [41,43–45,48,56,58,61,64,65], nine used milk drinks [47,50–52,55,60,66–68], 
six involved fruit and vegetable juices [53,54,62,63,71,72], and five involved yoghurt  
drinks [47,49,60,69,70]. The primary outcome of the majority of trials was BP change, however the 
primary outcome of three [63–65] studies was the safety of excessive LTP intake; and three had vascular 
reactivity as primary outcomes [43,44,50].  
3.3. Summary Results of the Effect of LTP Intervention 
In pooled analysis, LTP supplementation reduced office SBP by 2.95 mmHg (95% CI: −4.17, −1.73; 
p < 0.001) and reduced office DBP by 1.51 mmHg (95% CI: −2.21, −0.80; p < 0.001). The pooled effects 
both for SBP (I2 = 77%, Tau2 = 6.6, Chi2 = 141.0, degree of freedom (df) = 32, p < 0.001) and DBP (I2 48%, 
Tau2 = 1.6, Chi2 = 62.1, df = 32, p-value = 0.001) were heterogeneous (Figures 1 and 2). Using AMBP 
results, LTP supplementation showed a tendency for reduction in both SBP (−0.94 mmHg, 95% CI: −2.06, 
0.18, p = 0.101) and DBP (−0.46 mmHg, 95% CI: −1.11, 0.19, p = 0.166) although this did not reach 
statistical significance. The pooled effects for both SBP (I2 = 29%, Tau2 = 0.9, Chi2 = 12.6, df = 9,  
p = 0.182) and DBP (I2 = 4%, Tau2 = 0.1, Chi2 = 8.3, df = 8, p = 0.040) appear to be homogenous. 
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Table 1. Trial characteristics of studies included in the meta analysis 1. 
Reference 
Subject Group, n (M/F), 
Average Age and BMI 
Study Design 
and 
Duration 
Country Treatment 
Tripeptide 
(mg/day) 
Baseline 
BP  
Measure-Ment 3 
IPP VPP SBP (mmHg) 2 
DBP 
(mmHg) 2 
Hata et al.  
1996 [55] 
hypertensive, 30 (8/22),  
(26 on BP ↓ medicine),  
74.8 years, 20.5 kg/m2 
R, NR, C, 
PAL;  
8 weeks 
Japan 
L. helveticus and S. cerevisiae;  
1 × 100 mL milk drink 
1.10 1.50 
T: 158.5 ± 45.8  
C: 150.9 ± 34.2 
88.7 ± 38.8  
87.0 ± 32.8 
Office 
Kajimoto et al. 
2001 [56] 
normotensive, 43 (20/23),  
29.7 years, 21.5 kg/m2 
R, D, C, 
PAL;  
2 weeks 
Japan L. helveticus CM4; 1 × 6 tablets 4.50 8.10 
T: 113.6 ± 12.0  
C: 114.1 ± 10.5 
67.3 ± 8.7  
68.1 ± 7.6 
Office 
Kajimoto et al. 
2002 [57] 
mild hypertensive, 64 (33/31),  
50 years, 25.1 kg/m2 
R, D, C, 
PAL;  
8 weeks 
Japan 
L. helveticus and S. cerevisiae,  
L. helveticus CM4, L. 
delbrueckii bulgaricus, S. 
thermophilus 2 × 150 mL 
yoghurt drink 
1.58 2.24 
T: 148 ± 9  
C: 148 ± 9 
94 ± 7  
95 ± 7 
Office 
Seppo et al.  
2002 [68] 
mild hypertensive, 17 (5/12), 
47.5 years, 27.2 kg/m2 
R, D, C, 
PAL;  
8 weeks 
Finland 
L. helveticus LBK-16 H;  
1 × 150 mL milk drink 
2.25 3–3.75 
T: 148 ± 12.6  
C: 148 ± 13.3 
94 ± 6.3  
93 ± 2.7 
Office 
Seppo et al.  
2003 [66] 
hypertensive, 39 (19/20),  
(16 on BP ↓ medicine),  
49.4 years, NR 
R, D, C, PAL; 
21 weeks 
Finland 
L. helveticus LBK-16 H;  
1 × 150 mL milk drink 
2.25 3.00 
T: 152 ± 12.7  
C: 149 ± 11.1 
96 ± 5.2  
95 ± 5.8 
Home 
Nakamura et al. 
2004 [59] 
high-normotensive, 106 (34/72), 
38.5 years, 22.1 kg/m2 
R, D, C, PAL; 
12 weeks 
Japan 
L. helveticus and S. cerevisiae,  
L. helveticus CM4, L. 
delbrueckii bulgaricus, S. 
thermophilus 2 × 150 mL 
yoghurt drink 
1.48 2.26 
T: 134 ± 5  
C: 135 ± 4 
79 ± 5  
78 ± 5 
Office 
Mizushima et al. 
2004 [60] 
hypertensive, 46 M, 46.5 years,  
25 kg/m2 
R, D, C, 
PAL;  
4 weeks 
Japan 
L. helveticus and S. cerevisiae;  
1 × 160 mL milk drink 
1.15 1.98 
T: 147.6 ± 9.6  
C: 145.3 ± 13.0 
95.3 ± 9.9  
91.5 ± 9.6 
Office 
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Table 1. Cont. 
Toulomilehto  
et al. 2004 [52] 
mild hypertensive, 59 (36/23), 
52.8 years, 28.6 kg/m2 
R, D, C, CO; 
13–17 weeks 
Finland 
L. helveticus LBK-16 H;  
1 × 150 mL milk drink 
2.4–2.7 2.4–2.7 
T: 152.7 ± 10.0  
C: 156.6 ± 11.4 
98.1 ± 7.2  
98.1 ± 7.0 
Office 
Aihara et al.  
2005 [61] 
high-normotensive, 40 (26/14), 
51.4 years, 24.2 kg/m2 
R, D, C, 
PAL;  
4 weeks 
Japan L. helveticus CM4; 1 × 6 tablets 4.70 8.30 
T: 137.4 ± 5.1  
C: 136.8 ± 6.1 
85.1 ± 4.9  
84.8 ± 11.0 
Office 
 
mild hypertensive, 40 (32/8), 
51.7 years, 25 kg/m2 
     
T: 148.8 ± 7.2  
C: 146.6 ± 8.7 
92.6 ± 11.9  
92.1 ± 8.7 
 
Jauhiainen et al. 
2005 [67] 
hypertensive, 108 (69/39),  
53 years, 28.5 kg/m2 
R, D, C, PAL; 
10 weeks 
Finland 
L. helveticus LBK-16 H;  
2 × 150 mL milk drink 
IPP VPP SBP (mmHg)2 
DBP 
(mmHg)2 
Office 
Mizuno et al. 
2005 4 [48] 
high-normotensive, 24 (6/18), 
42.8 years, 25 kg/m2 
R, S, C, 
PAL;  
6 weeks 
Japan 
A. oryzae hydrolysate;  
1 × 2 tablets 
1.76 1.86 
T: 133.9 ± 6.7  
C: 132.8 ± 3.4 
81.2 ± 4.7  
80.2 ± 2.7 
Office 
 
mild hypertensive, 41 (20/21), 
45.9 years, 22.8 kg/m2 
     
T: 148.0 ± 6.3  
C: 148.4 ± 7.6 
88.1 ± 6.2  
88.6 ± 3.7 
 
Sano et al.  
2005 [62] 
hypertensive, 144 (57/87),  
50.5 years, 24 kg/m2 
R, D, C, 
PAL;  
12 weeks 
Japan 
A. oryzae hydrolysate;  
1 × 200 mL vegetable-fruit juice 
1.60 1.47 
T: 138.2 ± 6.5  
C: 138.5 ± 6.7 
84.4 ± 5.3  
85.2 ± 5.7 
Office 
Sano et al.  
2005 [63] 
normotensive and hypertensive, 
43 (21/22), 46.9 years,  
23.6 kg/m2 
R, D, C, 
PAL;  
4 weeks 
Japan 
A. oryzae hydrolysate;  
3 × 200 mL vegetable-fruit juice 
4.80 4.41 
T: 132.3 ± 17.0  
C: 133.1 ± 15.3 
80.6 ± 9.2  
82.3 ± 9.5 
Office 
Ishida et al.  
2006 [65] 
normotensive and hypertensive, 
54 (16/38), 51.9 years,  
24.9 kg/m2 
R, D, C, 
PAL;  
4 weeks 
Japan 
A. oryzae hydrolysate;  
1 × 20 tablets 
10.10 5.65 
T: 131.4 ± 15.2  
C: 133.4 ± 15.9 
81.9 ± 10.8  
83.7 ± 10.9 
Office 
Engberink et al. 
2008 [69] 
hypertensive, 35 (23/12),  
58.8 years, 26.9 kg/m2 
R, D, C, 
PAL;  
8 weeks 
the 
Netherlands 
fermentation; 1 × 200 mL  
low-fat yoghurt drink 
4.20 5.80 142.0 ± 11.3 83.2 ± 8.3 Office 
 
hypertensive, 32 (22/10),  
54.2 years, 26.8 kg/m2 
  
enzymatic hydrolysis;  
1 × 200 mL low-fat  
yoghurt drink 
5.40 5.00 141.6 ± 13.6 85.5 ± 10.8 Office 
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Table 1. Cont. 
 
hypertensive, 36 (23/13),  
59.5 years, 27.0 kg/m2 
  
chemical synthesis;  
1 × 200 mL low-fat  
yoghurt drink 
5.20 5.00 142.2 ± 12.6 81.9 ± 10.8 Office 
 
hypertensive, 32 (20/12),  
58.9 years, 26.8 kg/m2 
  
placebo; 1 × 200 mL low-fat 
yoghurt drink 
0.00 0.00 140.7 ± 13.0 83.9 ± 7.4 Office 
van der Zander  
et al. 2008 [70] 
mild hypertensive,  
275 (153/122), 60 years,  
26.7 kg/m2 
R, D, C, 
PAL;  
8 weeks 
the 
Netherlands 
A. oryzae hydrolysate;  
1 × 200 mL yoghurt drink 
5.78 4.40 
150 ± 12.8  
150 ± 12.9 
85.2 ± 9.2  
86.2 ± 9.3 
Office 
van Mierlo et al. 
2009 5 [46] 
mild hypertensive, 69 (45/24), 
61.7 years, 26.9 kg/m2 
R, D, C, CO; 
8 weeks 
Scotland 
A. oryzae hydrolysate;  
1 × 200 mL yoghurt drink 
5.78 4.40 147.4 ± 9.0 89.0 ± 5.9 Office 
de Leeuw et al. 
2009 2 [49] 
mild hypertensive, 41 (21/20), 
59.5 years, 25 kg/m2 
R, D, C, 
PAL;  
8 weeks 
the 
Netherlands 
A. oryzae hydrolysate;  
1 × 200 mL yoghurt drink 
4.56 4.47 
149 ± 15  
148 ± 13 
85 ± 8  
85 ± 9 
Office 
Yoshizawa et al. 
2009 6 [43] 
normotensive, 28 F, 58 years,  
21.7 kg/m2 
R, S, C, 
PAL;  
8 weeks 
Japan 
enzymatic hydrolysis;  
1 × 8 tablets 
4.30 2.40 
116 ± 20.8  
110 ± 19.0 
68 ± 10.4  
66 ± 12.6 
Office 
Yoshizawa et al. 
2010 6 [44] 
normotensive, 22 F, 57.5 years,  
22 kg/m2 
R, S, C, 
PAL;  
8 weeks 
Japan 
enzymatic hydrolysis;  
1 × 8 capsules 
4.30 2.40 
112 ± 23.4  
104 ± 14.4 
76 ± 11.7  
72 ± 10.8 
Office 
Cicero et al.  
2010 [53] 
normo- and high-normotensive, 
55 (30/25), 40.3 years, 25 kg/m2 
R, D, C, CO; 
4 weeks 
Italy 
enzymatic hydrolysis;  
2 × 250 mL vegetable and  
fruit juice 
2.00 4.00 126.0 ± 15.5 80.3 ± 8.7 Office 
Jauhiainen et al. 
2010 4 [50] 
hypertensive, 89 (54/35),  
49 years, 28.1 kg/m2 
R, D, C, 
PAL;  
12 weeks 
Finland 
L. helveticus LBK-16 H;  
2 × 200 mL fermented milk 
11.60 13.20 
151.3 ± 14.8  
154.6 ± 13.9 
95.2 ± 12.2  
94.2 ± 8.8 
Office 
Boelsma, Kloek 
2010 7 [45] 
stage 1 hypertensive, 26 (17/9),  
59 years, 26.5 kg/m2 
R, D, C, CO; 
4 weeks 
the 
Netherlands 
enzymatic hydrolysis;  
2 ×1 capsules 
15.00 - 148.7 ± 11.5 89.2 ± 10.1 Office 
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Table 1. Cont. 
Usinger et al. 
2010 4 [47] 
mild hypertensive, 60 (28/32),  
54 years, 26.5 kg/m2 
R, D, C, 
PAL;  
8 weeks 
Denmark 
fermentation; 1 × 300 mL 
fermented milk 
2.50 1.10 
145 ± 10.9  
136 ± 8.8 
92.6 ± 6.4  
89.4 ± 7.6 
Office 
Germino et al. 
2010 [72] 
hypertensive, 81 (45/36),  
57.1 years, 29.5 kg/m2 
R, D, C, 
PAL;  
6 weeks 
USA 
2 × 1 (75 mg) powder dissolved 
in apple juice 
NR NR 
156.6 ± 6  
154.6 ± 6 
92.5 ± 8.3  
91.6 ± 9.6 
Office 
Ishida et al.  
2011 [64] 
normo- and mild hypertensive,  
48 (24/24), 49.3 years,  
22.4 kg/m2 
R, D, C, 
PAL;  
4 weeks 
Japan 
A. oryzae hydrolysate;  
1 × 20 tablets 
9.60 7.50 
130.6 ± 16.3  
131.8 ± 14.8 
80.4 ± 10.6  
81.1 ± 9.6 
Office 
Nakamura et al. 
2011 [58] 
hypertensive, 70 (47/23),  
57.8 years, 23.9 kg/m2 
R, D, C, 
PAL;  
8 weeks 
Japan 
A. oryzae hydrolysate;  
1 × 4 tablets 
1.90 1.50 
146.8 ± 4.4  
146.9 ± 4.3 
87.5 ± 7.1  
88.0 ± 7.7 
Office 
Cicero et al.  
2011 [71] 
high-normotensive and mild 
hypertensive, 50 (29/21),  
51.2 years, 26.8 kg/m2 
R, D, C, 
PAL;  
6 weeks 
Italy 
enzymatic hydrolysis;  
1 × 250 mL fruit juice 
1.00 2.00 
142.0 ± 10.9  
141.2 ± 9.6 
86.4 ± 8.2  
86.6 ± 7.7 
ABPM 
Cicero 2012 [54] 
high-normotensive and mild 
hypertensive, 164 (101/63),  
43.9 years, 25.7 kg/m2 
R, D, C, CO; 
4 weeks 
Italy 
enzymatic hydrolysis;  
1 × 250 mL fruit juice 
1.00 2.00 
T: 133.5 ± 12.9  
C: 132.7 ± 12.5 
83.3 ± 8.8  
82.8 ± 8.3 
Office 
Jauhiainen  
2012 [51] 
mild hypertensive, 89 (54/35),  
49 years, 28.1 kg/m2 
R, D, C, 
PAL;  
12 weeks 
Finland 
L. helveticus LBK-16 H;  
1 × 200 mL fermented milk 
2.40 2.60 
T: 148 ± 7  
C: 147 ± 5 
95 ± 5  
94 ± 4 
ABPM 
  12 weeks  2 × 200 mL fermented milk 23.20 26.40 
T: 147 ± 8  
C: 145 ± 8 
94 ± 6  
93 ± 6 
ABPM 
1 ABPM, ambulatory blood pressure monitor; C, controlled; CO, cross-over; BP, blood pressure; D, double blind; DB, diastolic blood pressure; NR, not reported; PAL, parallel; P, placebo group; R, randomised; S, 
single blind; SB, systolic blood pressure; T, treatment group; ↓, lowering; 2 mean ± SD; 3 Reported method of measurement used in meta-analysis; 4 Data from participants assigned to the highest dose; 5 Data from 
participants assigned to LTP only; 6 Data from participants assigned to LTP without exercise; 7 Data from participants assigned to IPP only and with stage I hypertension. 
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Figure 1. Overall change in SBP (mmHg) after LTP supplementation. HN,  
high-normotensives; MH, mild-hypertensives; 0.000 refers to p<0.001. Weighted mean 
difference (95% CI), random effects model. Q = 141.01, df = 32, p < 0.001, I2 = 77%. 
We conducted sub-group analyses (Table 2.) on the 33 included trials. The effect of baseline SBP and 
DBP did not influence the effect size significantly; however participants with elevated BP at baseline 
appeared to have a greater SBP and DBP reduction after LTP supplementation. The length of treatment 
had no statistically significant impact on the effect size; however trials with equal to or shorter than eight 
weeks treatment reported a greater decrease in BP. A smaller dose of LTP (≤10 mg/day) had significantly 
greater BP reduction than larger dose (p = 0.027 for SBP, p = 0.015 for DBP). The method of LTP 
production showed no significant effect on BP-lowering. The country in which the study was performed 
significantly influenced the treatment effect. All trials were separated into two categories: Japanese and 
European countries (we excluded the American trial, due to the lack of other studies in the USA). 
Although both sub-groups showed statistically significant reduction in BP, trials from Japan resulted in 
significantly greater BP-lowering compared to studies from European countries (p = 0.002 for SBP and 
p < 0.001 for DBP). 
  
Study name Sta tisti cs fo r  each  study Di ffe rence  in  means and  9 5 % CI
Di ffe rence  Lower  Upper  Re la ti ve  Re la ti ve  
in  means l imi t l imi t p -Va lue we igh t we igh t
Hata 1996 (55) -9.7 -19.0 -0.4 0.041 1.34
Kajimoto 2001 (56) -3.0 -9.6 3.6 0.376 2.15
Kajimoto 2002 (57) -13.0 -18.2 -7.8 0.000 2.87
Seppo 2002 (68) -10.8 -21.6 -0.0 0.050 1.05
Seppo 2003 (66) -6.0 -13.4 1.4 0.114 1.85
Nakamura 2004 (59) -4.0 -6.7 -1.3 0.004 4.56
Mizushima 2004 (60) -1.5 -7.7 4.7 0.636 2.34
Tuomilehto 2004 (52) -1.9 -5.0 1.2 0.233 4.26
Aihara 2005 HN (61) -3.2 -9.0 2.6 0.276 2.56
Aihara 2005 MH (61) -11.2 -18.4 -4.0 0.002 1.93
Jauhiainen 2005 (67) -2.0 -5.7 1.7 0.285 3.86
Mizuno 2005 HN (48) -3.1 -7.6 1.4 0.175 3.29
Mizuno 2005 MH (48) -11.8 -17.6 -6.0 0.000 2.51
Sano 2005 (62) -3.8 -6.1 -1.5 0.002 4.85
Sano 2005 (63) -4.8 -14.0 4.4 0.308 1.35
Ishida 2006 (65) 1.8 -6.4 10.0 0.666 1.62
Engberink 2008 (69) 1.4 -2.3 5.0 0.471 3.85
van der Zander 2008 (70) 0.4 0.3 0.5 0.000 5.90
van Mierlo 2009 (46) 0.0 -3.5 3.5 1.000 4.01
de Leeuw 2009 (49) 1.0 -5.5 7.5 0.763 2.21
Yoshizawa 2009 (43) -5.0 -18.3 8.3 0.462 0.74
Yoshizawa 2010 (44) -5.0 -21.8 11.8 0.559 0.49
Cicero 2010 (53) -1.2 -2.7 0.3 0.123 5.42
Jauhiainen 2010 (50) -2.0 -7.6 3.6 0.483 2.64
Boelsma & Kloek 2010 (45) -3.8 -6.5 -1.1 0.006 4.56
Usinger 2010 (47) -3.2 -8.0 1.6 0.188 3.11
Germino 2010 (72) 0.8 -3.9 5.5 0.738 3.16
Ishida 2011 (64) -6.8 -15.1 1.5 0.109 1.58
Nakamura 2011 (58) -6.7 -11.4 -2.0 0.005 3.13
Cicero 2011 (71) -0.5 -5.3 4.3 0.839 3.07
Cicero 2012 Office (54) -4.2 -6.7 -1.8 0.001 4.75
Jauhiainen 2012 one dose (51) 1.7 -1.1 4.5 0.236 4.50
Jauhiainen 2012 two doses (51) -1.8 -4.6 1.0 0.209 4.50
-3.0 -4.2 -1.7 0.000
- 2 0 . 0 0 - 1 0 . 0 0 0 . 0 0 1 0 . 0 0 2 0 . 0 0
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Figure 2. Overall change in DBP (mmHg) after LTP supplementation. HN,  
high-normotensives; MH, mild-hypertensives; 0.000 refers to p<0.001. Weighted mean 
difference (95% CI), random effects model. Q = 62.13, df = 32, p = 0.001, I2 = 49%. 
Table 2. Sub-group analyses. 
Sub-group Title No. of Trials 
Effect Size (mmHg) (95% CI) 
SBP DBP 
Baseline BP    
above 140/90 mmHg 20/12 −3.00 (−4.71, −1.29) −1.90 (−3.38, −0.42) 
below 140/90 mmHg 13/21 −2.68 (−3.61, −1.74) −1.38 (−2.13, −0.63) 
p-value *  0.748 0.541 
Duration of intervention    
≤8 weeks 25 −3.35 (−4.91, −1.79) −1.80 (−2.72, −0.89) 
>8 weeks 8 −2.18 (−3.72, −0.64) −1.00 (−2.10, −0.09) 
p-value *  0.966 0.921 
Dose of LTP    
≤10 mg/day 21 −3.81 (−5.30, −2.32) −2.02 (−2.87, −1.16) 
>10 mg/day 11 −1.32 (−2.94, 0.30) −0.41 (−1.38, 0.57) 
p-value *  0.027 0.015 
Production of LTP    
Enzymatic hydrolysis 14 −2.77 (−4.48, −1.05) −1.25 (−2.03, −0.47) 
Fermentation 15 −3.82 (−5.80, −1.84) −2.38 (−3.77, −1.00) 
p-value *  0.433 0.164 
  
Study name Sta tisti cs fo r  each  study Di ffe rence  in  means and  9 5 % CI
Di ffe rence  Lower  Upper  Re la ti ve  Re la ti ve  
in  means l imi t l imi t p -Va lue we igh t we igh t
Hata 1996 (55) -4.4 -10.9 2.1 0.184 1.02
Kajimoto 2001 (56) -3.0 -9.6 3.6 0.376 0.98
Kajimoto 2002 (57) -8.4 -12.1 -4.7 0.000 2.52
Seppo 2002 (68) -6.9 -13.0 -0.7 0.028 1.12
Seppo 2003 (66) -3.8 -7.6 -0.0 0.050 2.39
Nakamura 2004 (59) -3.5 -6.1 -0.9 0.008 3.84
Mizushima 2004 (60) -1.7 -7.2 3.8 0.545 1.35
Tuomilehto 2004 (52) -0.9 -2.4 0.6 0.233 5.89
Aihara 2005 HN (61) -5.0 -9.9 -0.1 0.045 1.63
Aihara 2005 MH (61) -6.5 -13.0 0.0 0.052 1.00
Jauhiainen 2005 (67) 1.0 -1.3 3.3 0.387 4.35
Mizuno 2005 HN (48) -0.4 -4.2 3.4 0.835 2.42
Mizuno 2005 MH (48) -2.9 -7.3 1.5 0.193 1.94
Sano 2005 (62) -1.7 -3.5 0.1 0.057 5.32
Sano 2005 (63) -1.5 -6.9 3.9 0.584 1.40
Ishida 2006 (65) 2.5 -3.1 8.1 0.381 1.31
Engberink 2008 (69) 0.8 -1.2 2.7 0.439 5.01
van der Zander 2008 (70) 0.3 -0.8 1.4 0.595 6.66
van Mierlo 2009 (46) -0.6 -2.5 1.3 0.530 5.08
de Leeuw 2009 (49) 0.0 -2.8 2.8 1.000 3.55
Yoshizawa 2009 (43) -2.0 -10.6 6.6 0.649 0.61
Yoshizawa 2010 (44) -3.0 -12.1 6.1 0.519 0.55
Cicero 2010 (53) -1.2 -2.7 0.4 0.138 5.80
Jauhiainen 2010 (50) -2.0 -6.0 2.0 0.323 2.24
Boelsma & Kloek 2010 (45) -2.3 -3.9 -0.7 0.005 5.62
Usinger 2010 (47) -1.7 -4.8 1.4 0.288 3.07
Germino 2010 (72) -0.9 -4.9 3.1 0.658 2.23
Ishida 2011 (64) -3.7 -9.2 1.8 0.191 1.33
Nakamura 2011 (58) -3.7 -8.0 0.6 0.092 1.99
Cicero 2011 (71) -0.4 -4.3 3.5 0.840 2.31
Cicero 2012 Office (54) -3.1 -4.9 -1.3 0.001 5.19
Jauhiainen 2012 one dose (51) 1.0 -0.9 2.9 0.295 5.08
Jauhiainen 2012 two doses (51) -0.7 -2.5 1.1 0.452 5.18
-1.5 -2.2 -0.8 0.000
- 1 2 . 5 0 - 6 . 2 5 0 . 0 0 6 . 2 5 1 2 . 5 0
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Table 2. Cont. 
Country of studies    
Japan 16 −5.54 (−7.43, −3.65) −3.01 (−4.25, −1.78) 
European countries 16 −1.36 (−2.53, −0.20) −0.83 (−1.57, −0.10) 
p-value *  0.002 <0.001 
Trial size    
<50 participants 15 −4.93 (−6.78, −3.07) −2.40 (−3.42, −1.39) 
≥50 participants 18 −1.99 (−3.31, −0.66) −1.11 (−1.96, −0.26) 
p-value *  0.011 0.057 
* Significant test to investigate the difference of between sub-groups, p < 0.05. 
Meta-regression analyses on the BMI of participants suggested a statistically significant negative 
association between BMI and BP lowering of LTP (slope coefficient: −24.8, p < 0.001 for SBP; and 
slope coefficient: −14.4, p = 0.001 for DBP) and no association between BP reduction and age (slope 
coefficient: −6.3, p = 0.392 for SBP; and slope coefficient: −5.1, p = 0.134 for DBP). Similarly, no 
statistically significant association was found between treatment effect and LTP dose (slope coefficient: 
−3.6, p = 0.297 for SBP; and slope coefficient: −2.0, p = 0.130 for DBP). Study quality analysis was 
performed, which showed that after removing the low quality trials (n = 14) the treatment effect shifted 
to −1.58 mmHg (95% CI: −2.80, −0.35; p = 0.012) for SBP and to −0.82 mmHg (95% CI: −1.60, −0.04; 
p = 0.039) for DBP. 
3.4. Risk of Bias within and across Studies 
The information regarding sequence generation and allocation concealment was rarely reported in the 
included RCTs. Only six studies described both sufficiently [53,54,58,69–71] and only three trials 
specified the allocation concealment [45,46,49]. Most of the trials lacked detailed information regarding 
participant blinding or whether outcome data assessors were blinded. Six studies [43,44,48,56,57,68] 
failed to clarify withdrawals and another [64] appeared to have reporting bias. All trials, apart from 
Cicero et al. 2010 [53], 2011 [71] and 2012 [54], were supported by industrial sponsors who provided 
the treatment products, furthermore many authors were employees of the sponsor companies. We identified 
13 studies of low, 14 of medium and only three of high quality (see Supplemental Table S1.). 
The visual assessment of funnel plots (standard error on y axis and difference in means on x axis) 
(see Supplemental Figures S2 and S3.) suggested asymmetry for both SBP and DBP. Begg and 
Mazumdar rank correlation test showed that tau for SBP was 0.05 and p-value = 0.664 and for DBP was 
−0.22, p-value = 0.070. Egger’s test reported intercept of −1.60 and p < 0.001 for SBP; and −1.23 and  
p = 0.01 for DBP. The trim and fill analysis estimated that nine publications might be missing for SBP 
(therefore adjusted values were −1.64 mmHg, 95% CI: −2.80, −0.47) and 11 for DBP (adjusted values 
were −0.63 mmHg, 95% CI: −1.41, 0.14). Since the funnel plot asymmetry might also arise from other 
possible sources [73], we compared the fixed and random effects estimates of the intervention effects. 
The pooled effect with fixed effects model showed an increase in SBP (0.34 mmHg, 95% CI: 0.24, 0.44; 
p < 0.001) after LTP supplementation, with a significant reduction in DBP (−1.11 mmHg, 95% CI: 
−1.55, −0.68; p < 0.001). Therefore we investigated the “small-study effect”. The sub-group analysis of 
samples sizes (categorised as small n < 50, other n ≥ 50) showed that the pooled effect of small studies 
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was −4.93 mmHg, 95% CI: −6.78, −3.07; p < 0.001 for SBP, and −2.40 mmHg, 95% CI: −3.42, −1.39; 
p < 0.001 for DBP. Effect of sample size ≥50 for SBP was −1.99 mmHg (95% CI: −3.31, −0.66;  
p = 0.003), and for DBP was −1.11 mmHg (95% CI: −1.96, −0.26; p = 0.011). Statistically significant 
differences between study sizes were identified for SBP (p = 0.011) and a near significant difference for 
DBP (p = 0.057). The meta-regression analysis to examine the relationship between study effect and 
sample size suggested that there was a significant negative association between sample size and 
treatment effect for SBP (slope coefficient: −4.5, p = 0.05) and tended to be significant for DBP (slope 
coefficient: −2.3, p = 0.083). 
4. Discussion 
The aim of this paper was to determine the association between LTP consumption and BP by 
performing a meta-analysis of the relevant literature to date. This analysis included 30 RCTs, extending 
previous meta-analyses on LTP supplementation [6–9] (for comparison of included studies among  
meta-analyses, see Supplemental Table S2.). We found that LTP supplementation modestly, but 
significantly reduced SBP (−2.95 mmHg) and DBP (−1.51 mmHg). The significant reductions in SBP 
and DBP after consumption of LTP observed in this study support previous data from meta-analyses on 
LTP [6–9], however to different extents (Supplemental Figures S4 and S5.). 
There was statistically significant heterogeneity of treatment effects across studies, which was higher 
for SBP. The included studies varied in many aspects such as dose, participant characteristics, duration 
of intervention and food matrices used, which could have contributed to heterogeneity. The higher 
heterogeneity of SBP is likely to be due to its variable nature compared to DBP [74]. The  
meta-analysis on 24-h AMBP did not result in statistically significant reductions in BP, which is in part 
in line with the study of Qin et al. [9]. They reported statistically significant reduction in SBP (−1.30, 
95% CI: −2.49, −0.11) and non-significant reduction in DBP (−0.57, 95% CI: −1.49, 0.35). 
Within our analysis we observed that the country in which studies were performed had a significant 
influence on treatment effect. This is in line with the findings of Cicero et al. where BP lowering of LTP 
consumption was more evident in Japanese and Finnish studies [7]. Furthermore, in the meta-analysis 
of Cicero et al. which focused on European subjects only, BP-lowering of LTP ingestion was reported 
(−1.28 mmHg, 95% CI: −2.09, −0.48 for SBP and −0.59 mmHg, 95% CI: −1.18, −0.01 for DBP) [75]. 
Our sub-group analyses of European studies showed similar results: −1.36 mmHg (95% CI: −2.53, 
−0.20) for SBP and −0.83 mmHg (95% CI: −1.57, −0.10) for DBP. It is known that there are ethnic 
differences in response to cardiovascular drugs, specifically BP-lowering drugs [76], which might be 
due to genetic polymorphism or environmental factors such as diet. Another possible explanation for the 
differences in the response in the Japanese studies, compared with European studies, may be the 
participants’ habitual milk and dairy consumption. The Japanese diets typically contain low quantities 
of milk and dairy products, which may impact on the BP responses to inclusion of LTP in their diet [77]. 
In 2009 Japanese fluid milk consumption was 32.2 kg/capita/year, whereas Europe consumed  
64.5 kg/capita/year [78]. However it is of note that there was a lack of information on the dietary intake 
(milk, dairy products, fermented food or salt intake) of the participants in the studies included in this 
analysis. Lack of dietary data is a substantial limitation as this information would provide valuable data 
on the possible impact of habitual dietary intake and responsiveness to LTP supplementation. 
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Furthermore, a recent study of Siltari et al. [79] found that the peptides can have four different spatial 
conformations (cis/trans) owing to the fermentation process (bacteria) or synthesis. This may have 
important impact on the biological activity of the products produced in different countries, which may 
explain the different effects of LTP consumption in different countries. Likewise, it is important to note 
that different forms of LTP have been tested in the studies included in the meta-analysis, which may 
have also influenced the high variability observed. 
We found a significant negative association between BMI and BP lowering effects of LTP (p < 0.001 
for SBP and p = 0.001 for DBP). Although BMI and BP are highly positively correlated [80], our results 
are contradictory to this dogma. The BMI of Japanese participants were lower (average BMI was  
23 kg/m2) than the Caucasians (average BMI was 27 kg/m2), yet LTP resulted in significant BP lowering 
in Japanese subjects. It may be that the smaller body weight of Japanese subjects could also influence 
the effective concentration of the peptides in the body. Nevertheless this paradoxical finding could 
simply reflect the greater BP reduction reported in the Japanese studies compared with trials from other 
countries and may support the identified publication bias. However it is important to note that  
meta-regression analysis has the same disadvantage as epidemiological studies: bias by confounding. It 
is a recognised “pitfall” in meta-analyses when the predictor is a subject-level characteristic that has 
been averaged over study subjects [81,82]. 
We found that low LTP doses are common in the Japanese studies with an average dose of  
7.57 mg/day, compared with 11.68 mg/day for European studies. The negative relationship between dose 
and effect may reflect the reported greater BP reduction in this population. To establish whether there is 
a true negative relationship between BMI, LTP dose and hypertensive effects of LTP, a dose-dependent 
study in the same population with varying BMI is required. This will help to reduce population bias and 
other potential confounding factors between different population groups. 
Whilst considering the risk of bias of the included studies, it was found that trial methodological 
quality was better in the European studies which involved large numbers of participants [46,69,70], yet 
these studies showed no significant effects of LTP on BP. Thus, it is likely that the smaller studies made 
the largest contribution to the observed significant treatment effect from the meta-analysis. This is a 
recognised phenomenon known as the “small-study effect”, which could have impacted significantly on 
the differential results from the different groups [73]. Our investigation suggested a modest “small-study 
effect”, which was more evident in DBP. However when the lower quality trials were removed, and the 
meta-analysis was repeated, a statistically significant reduction in BP remained. This is in part consistent 
with our trim and fill analysis, which enables us to estimate how the treatment effect would shift if all 
studies were available and included in the meta-analysis (assuming no publication bias). Taken together, 
we concluded that it is likely that some bias influenced the treatment effect, and if so, this might shift 
the pooled effect of LTP supplementation towards a less significant reduction in SBP and non-significant 
reduction in DBP. 
A key conclusion of this meta-analysis is that inclusion of LTP in the diet has significant hypotensive 
effects. Although the effect is usually less than many antihypertensive drugs (all drugs total −14.5 mmHg 
in SBP and −10.7 mmHg in DBP [83]), LTP represents a potentially important prophylactic strategy for 
reducing the risk of hypertension through the lifespan, which could reduce the need for antihypertensive 
medication later in life. Moreover, the use of such drugs has been associated with adverse effects such 
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as dizziness, headache and swelling and even hypotension in normotensive individuals [84] which have 
not been reported for LTP use. 
5. Strengths of the Meta-Analysis 
The present study has a number of strengths and presents the most comprehensive treatment effect of 
LTP. This study used the most thorough and precisely defined inclusion criteria and followed the 
PRISMA guideline. Similarly, the literature search was rigorous and robust. This meta-analysis included 
all available RCT to date that met our robust criteria for inclusion, resulting in 30 trials with 33 sets of 
data. The high number of RCT allowed the most comprehensive subgroup, meta-regression analyses and 
publication bias, which provided possible reasons for the observed heterogeneity in treatment effects. 
The LTP treatment effects were analysed using both office and AMBP, which is also unique. 
6. Limitation of the Meta-Analysis 
The main limitation was the lack of available data in the published manuscripts, which was due in a 
large part from poor reporting (e.g., lack of detail on statistical analysis, random sequence generation, 
allocation concealments and blinding of outcome assessments as well as the presentation of the results), 
particularly in the Japanese papers. Poor reporting style does not necessary reflect poor methodological 
research. However it might substantially affect the outcome of meta-analyses, and thus the future 
implications for practice. Therefore it is of paramount importance that manuscripts are written in an 
appropriate scientific style and format. Furthermore, the format in which the data were presented in 
many of the papers made data extraction difficult and may have influenced the extracted result. 
Contacting authors was not successful in every case, which could have reduced the possible errors of  
the analyses. 
7. Conclusions 
Supplementation of pre- or hypertensive groups with LTP for longer than four weeks resulted in  
a small, but significant reduction in SBP and DBP. However, when the potential biases were considered, 
the overall effect of LTP ingestion on BP appeared lower. Further studies are warranted to investigate 
the possible synergistic effects of LTP with some antihypertensive drugs in well-powered RTC. It is 
recommended that well designed trials with good reporting style and comprehensive information 
including ethnicity of studied groups and dietary intake of participants (e.g., milk and dairy consumption, 
salt intake) at baseline and during the intervention should be conducted. This will lead to a better 
understanding of the impact of LTP ingestion in BP therapy. 
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